GRA VentureLab Company Apica snags $5,100,000 in new investment
Apica Cardiovascular, a medical device company, has garnered new investment totaling $5.1 million from Ireland-based Seroba Kernel Life Sciences and Israel-based TriVentures.
Georgia Tech and Emory University researchers and clinicians developed the company’s lead technology, a system to simply and standardize opening and closing the beating heart during cardiac surgery. Apica CEO James Greene says that the technology has the potential to revolutionize the delivery of different types of medical devices to the heart, including aortic and mitral valves.
Early support from the Georgia Research Alliance VentureLab program and the Coulter Foundation Translational Research Program helped researchers complete a series of pre-clinical studies of the functionality and biocompatibility of the device. Read more>
Entry filed under: Commercialization/VentureLab. Tags: .